1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
FutureTech II Acquisition Corp.

FutureTech II Acquisition Corp.

FTII
FutureTech II Acquisition Corp.US flagOther OTC
12.02
USD
- -
- -
51.57MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
0.2
0.31
-0.29
-0.34
Free Cash Flow per Basic Share
- -
-0.17
-0.19
-0.76
-0.72
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
32.83
5.89
0.09
0.06
Tangible Book Value per Share
- -
32.83
5.89
0.09
0.06
Basic Weighted Avg Shares
- -
4
9
3
4
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
1
3
-1
-1
Effective Tax Rate (%)
- -
30.71
25.17
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
Working Capital
- -
- -
-4
-23
-5
LT Debt
- -
- -
- -
- -
- -
Total Equity
- -
115
55
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
3.43
-2.72
-11.14

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
4
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
43
40
41

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2
2
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
7
7
Payables & Accruals
20
3
3
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-99.59%
Free Cash Flow
- -
- -
9.03%
Net Income, GAAP
- -
- -
-125.66%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.23
0.24
0.19
- -
0.31
2024
0.04
-0.01
-0.04
- -
-0.29
2025
-0.08
-0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Ray Chen
Full Time Employees
1
Sector
Financial Services
Industry
Shell Companies
Address
128 Gail Drive New Rochelle NY United States of America 10805
IPO Date
Apr 8, 2022
CIK
0001889450
Website
futuretechii.com
Similar Companies
Sustainable Opportunities Acquisition Corp. (SOAC)
Consilium Acquisition Corp I, Ltd. (CSLMW)
Qell Acquisition Corp. (QELLU)
Nubia Brand International Corp. (NUBI)
Jackson Acquisition Company II (JACS-UN)
JAB Acquisition Corp I (JABRU)
Business
FutureTech II Acquisition Corp. operates as a blank check company, possessing no significant business activities of its own. Its fundamental objective involves pursuing a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar combination with one or more operating enterprises. The company had initially aimed its search towards entities within the technology sector. However, it has since announced a definitive business combination agreement with Longevity Biomedical, Inc., intending to form a Nasdaq-listed biopharmaceutical company focused on health and longevity. The combined entity was anticipated to trade under the symbol 'LBIO'. Incorporated in 2021, the company is situated in New Rochelle, New York. Recent developments include a delisting from Nasdaq, with the stock now trading on the OTC markets under a "position closing only" status.

Company News

APIChatGPT

  • globenewswire.com

    FutureTech II Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Publicly Held Shares Rule and Makes Progress Towards Regaining Compliance

  • globenewswire.com

    Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity